Chicago, IL, November 3, 2022 (PRNewswire) -- Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.
Read full article here.
South San Francisco, CA, March 14. 2023 (Business Wire) -- Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced i
San Diego, CA, March 14, 2023 (Globe Newswire) -- Medical Marijuana, Inc., a holding company with operating assets dedicated to the cannabis and hemp industries, along with portfolio investments in co
Cambridge, MA, March 6, 2023 (Business Wire) -- Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable anti-tumor response, today
